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Genital tract infections and cytokine perturbations are associated with increased HIV acquisition and transmission. We mea-
sured the relationship between bacterial vaginosis (BV) and concentrations of Interleukin-8 (IL-8), Interleukin-1β (IL-1β),
and Interleukin-6 (IL-6) in cervicovaginal lavage (CVL) specimens collected longitudinally from 16 HIV-infected and 8 HIV-
uninfected high-risk women. CVL samples were analyzed when women presented with BV, and at their next visit, after successful
treatment, when BV was cleared. A subset of participants had cytokine levels evaluated at three consecutive clinic visits: before
developing BV, at the time of BV diagnosis, and after clearing BV. Signiﬁcantly higher IL-8, but not IL-1β or IL-6 levels were
present when women had active BV compared to when BV was absent. Trends in cytokine levels were similar for HIV-infected and
HIV-uninfected women. BV in these women was associated with signiﬁcantly higher concentrations of genital tract IL-8 which
decreased 2.4 fold when BV was cleared.
Copyright © 2007 Phyllis Losikoﬀ et al.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Bacterial vaginosis (BV) is associated with higher risk of HIV
acquisition [1]. In HIV-infected women, BV is associated
with higher concentrations of HIV RNA in genital tract se-
cretions [2, 3]. Thus, BV may increase a woman’s risk of
transmitting HIV infection to her sexual partner or infant.
The exact mechanisms by which BV enhances HIV acquisi-
tionandviralsheddingarenotwellunderstood.Recentstud-
iessuggestthatBV’sroleinenhancingHIVtransmissionmay
be the result of both direct eﬀects of pathogenic microorgan-
ismsonHIVexpression,andindirecteﬀectsarisingfromBV-
relatedalterationsinthelocalmucosalimmuneenvironment
by increasing the expression of proinﬂammatory cytokines
[4, 5].
Proinﬂammatory cytokines such as Interleukin-1β (IL-
1β) and Interleukin-6 (IL-6) directly induce HIV-1 replica-
tion through NF-κB-mediated activation of HIV-1 long ter-
minal repeat [6]. Interleukin-8 (IL-8), which recruits cells
susceptible to HIV, directly enhances HIV replication in
macrophages and T-lymphocytes [7]. A recent study of note
by Narimatsu et al. demonstrated that IL-8 signiﬁcantly in-
creases susceptibility of cervical tissue to HIV infection [8].
Though BV is considered a noninﬂammatory disorder, sev-
eral cross-sectional studies have reported higher genital tract
concentrationsofproinﬂammatorycytokinesinwomenwith2 Infectious Diseases in Obstetrics and Gynecology
BV compared to healthy controls [9–12]. Thus, it is possi-
ble that higher genital tract HIV viral loads in HIV-infected
women and enhanced susceptibility to infection in seronega-
tive women may be mediated directly by the eﬀects of abnor-
mal microﬂora on genital tract cytokine expression.
The scientiﬁc understanding of the range of “normal”
genital tract cytokine concentrations is incomplete, partially
because these concentrations vary widely, partly due to host
factors including the local vaginal milieu and the genetic di-
versity of participants that cannot be controlled in cross-
sectional studies [13]. Investigations of BV and genital tract
cytokine concentrations have generally not included HIV-
infected women, despite their higher prevalence of BV and
the potential role BV could play in facilitating HIV transmis-
sion to sexual partners and oﬀspring.
The aim of the present study was to compare levels of the
cytokinesIL-1β,IL-6,andIL-8inHIV-infectedandhigh-risk
HIV-uninfected women in the presence and absence of BV.
Thesespeciﬁccytokineswerechosenbecauseoftheirdistinct
roles in HIV-1 pathogenesis and their possible use as surro-
gate biomarkers for vaginal inﬂammation. The longitudinal
study design eliminated individual variability when compar-
ing inﬂammatory cytokines in the genital tract. The use of
archived CVL specimens facilitated the selection of longitu-
dinal samples from women with clear changes in BV status
and avoidance of confounding factors that may impact the
ability to assess the eﬀects of BV on CVL cytokine concentra-
tions.
2. METHODS
Participants were chosen from women enrolled in the
HIV Epidemiological Research Study (HERS) in Providence
Rhode Island [14]. The HERS cohort included HIV-infected
and demographically matched high-risk controls who were
evaluated every six months in four U S urban centers from
1994 to 2001. At each visit, a complete pelvic exam was per-
formed that included collection of a cervicovaginal lavage
(CVL) specimen and a vaginal swab. We selected archived
samples from women who had been diagnosed with BV,
treated, and had no evidence of BV at the next consecu-
tive HERS visit, six months later. A subset of participants
was evaluated at three consecutive visits at six month inter-
vals. These women did not have BV at study entry which
was deﬁned as the “baseline” visit. They acquired BV while
they were HERS participants and they were treated, which
resulted in clearance of BV. Women who were pregnant or
had concomitant infection with Trichomonas vaginalis, Neis-
seria gonorrhea,o rChlamydia trachomatis at any of the visits
were not included in this study. Also excluded were women
who reported douching, having intercourse, or inserting any
intravaginal products into their vagina within the 48 hours
before CVL samples were obtained. A microscopic exam
of vaginal ﬂuid for sperm was performed. Specimens from
women who were menstruating, or if the practitioner could
visualize blood at the cervical os or in the vagina, at the time
of CVL collection at any visit, were not selected for inclusion
in this study. Diagnostic testing methods for this cohort have
been described in detail elsewhere [14]. Informed consent,
approved by the Miriam Hospital IRB Review Board, was
provided by all study participants. In this study, BV was di-
agnosed by the same expert gynecologist (SC) using Amsel’s
criteria. BV was considered to be present if any 3 of the fol-
lowing 4 conditions were noted: abnormal discharge, vaginal
pH > 4.7, the presence of clue cells on a wet mount of vaginal
secretions, or a positive “whiﬀ test.” A smear from the pos-
terior fornix was examined under oil immersion (x1000) to
determine the vaginalwhitecellcountand thepercentagesof
polymorphonuclear lymphocytes (PMNs) and monocytes.
CVLspecimens
CVL specimens were obtained by instilling 10ml of sterile
saline into the vaginal vault directing the stream of ﬂuid at
the cervical os. The ﬂuid was left for about 30 seconds and
then aspirated. The ﬂuid was then transferred to a sterile
15ml conical test tube and stored at −70◦C.
Cytokineassays
Frozen CVL samples were thawed and centrifuged at 500xg
to remove debris; they were then centrifuged at 2000xg and
supernatants were harvested. The resulting supernatant was
divided in two aliquots, and cytokine concentrations were
measured using commercial quantitative sandwich enzyme
immunoassay kits (Quantikine, R & D Systems, Minneapo-
lis, MN). All samples were run in duplicate and results were
reported in pg/ml. Samples were diluted 1 : 10 for IL-1β and
IL-8and1:4forIL-6accordingtomanufacturer’sdirections.
Assays yielding values below the limit of detection were left-
censored at the lower limit of detection, corresponding to
0.7pg/ml for IL-6, 10pg/ml for IL-8, and 1.0pg/ml for IL-
1β.
Dataanalysis
Sample medians and ranges were determined. Estimates of
the cumulative distribution function (CDF) were plotted by
BV status for each cytokine. Since genital tract cytokines
have complex distributions, CDF plots of cytokine concen-
trations for patients at consecutive visits, with and without
BV, provided the most comprehensive presentation of these
data [15]. A stratiﬁed Cox proportional hazards model was
usedtocomparethedistributionofcytokinelevelsbyBVsta-
tus, and by participant characteristics. The association of IL-
8andBVwasexaminedusingamultivariatelinearregression
model. Generalized estimating equations (GEE) were used
sincerepeatedmeasuresweretakenfromspecimensfromthe
same participants. Statistical analyses were performed using
SAS version 8.2 (SAS, Cary, NC) and R (www.r-project.org).
3. RESULTS
Participants
Longitudinal CVL samples from 24 women who were HERS
participants in Providence, Rhode Island were selected based
on their BV status at sequential visits; 16 of the womenPhyllis Losikoﬀ et al. 3
selected were HIV-infected and 8 were high-risk HIV-un-
infected. The mean age of these women was 31 years
(range 24.0–40.7); 16.7% were African-American, 20.8%
were Latin, and 62.5% were Caucasians. At baseline, the me-
dian log10 plasma HIV RNA concentration of HIV-infected
women was 3.04 (range: undetectable to 4.88), 31% (5/16)
had undetectable plasma HIV RNA concentrations and 25%
had CD4+Tc e l lc o u n t s<200cells/μl. Sixty eight percent
(11/16) of the HIV-infected women were on antiretroviral
regimensatthetimeofstudyentry.Allparticipantswerepre-
scribed oral metronidazole 500mg to be taken twice daily for
s e v e nd a y sw h e nB Vw a sd i a g n o s e d .
Cytokinedetection
IL-6, IL-8 and IL-1β concentrations in CVL samples were
evaluated from women who were selected for this study.
Concentrations of each of these cytokines in genital ﬂuids in
the presence and absence of BV were compared since BV is
associated with greater susceptibility to HIV and it was sus-
pected that BV might change the cytokine environment in
the genital tract. Of the 48 paired specimens from the 24 par-
ticipants, IL-8 was detected in 99%, IL-1β in 83%, and IL-6
was detected in 56% of all CVL samples.
AssociationsbetweencytokinesandBVstatus
Genital tract IL-8 concentrations were signiﬁcantly higher
when women were diagnosed with BV than after the same
women had cleared BV (Hazard ratio = 3.8, 95% CI 1.419,
10.177). In contrast, there was no signiﬁcant diﬀerence in
genital tract concentrations of IL-1β or IL-6 associated with
BV clearance (Figure 1). Trends in overall cytokine concen-
trations were similar in both HIV-infected and uninfected
participants; no statistically signiﬁcant interactions between
HIV and BV status were observed Table 1. Among the HIV-
infected women, there was no signiﬁcant diﬀerence in vagi-
n a lI L - 8c o n c e n t r a t i o n sb yB Vs t a t u sb e t w e e nw o m e nw h o
were on antiretroviral therapy compared to those who took
no antiretroviral drugs during the study (data not shown).
AdjustedassociationbetweenBVandIL-8
The within-subject changes in genital tract IL-8 concentra-
tion associated with BV status were evaluated by means of
a multivariate linear regression. After adjusting for the ef-
fects of ethnicity, HIV status, quantity of vaginal PMNs and
monocytes, and genital tract IL-1β concentrations, the asso-
ciationbetweenBVandincreasedgenitaltractIL-8remained
signiﬁcant. The transition from having BV to documented
clearance of BV was associated with a 2.4 fold decline in gen-
ital tract IL-8 concentration that was statistically signiﬁcant
(p = 0.02) and independent of the eﬀect of the other factors
controlled for in the regression model.
CytokinelevelsassociatedwithincidentBVandBVclearance
For 7 women, 5 HIV-infected and 2 high-risk HIV-uninfect-
ed, genital cytokine concentrations were evaluated at three
consecutive clinic visits each six months apart. These women
were BV negative at their initial visit, then they developed
BV and were diagnosed at their second visit. Treatment was
initiated and they were BV negative at their next visit. Par-
ticipants included in this analysis had no other concomitant
genital tract infection or other contraindication for CVL col-
lection at any of the three visits. Median concentrations and
ranges of genital tract IL-1β and IL-8 at baseline, before BV
diagnosis, at the time of BV diagnosis, and after BV clear-
anceare shown in Table 2. A GEEmodel comparing repeated
measures in the same women demonstrated a signiﬁcant in-
crease in mean genital tract IL-8 concentrations but not IL-
1β when women were diagnosed with BV compared to con-
centration of these cytokines when they did not have BV,
p = .004 and p = .51, respectively (Figure 2). IL-6 concen-
trations could not be evaluated as over 70% of the observa-
tions were below the level of detection of our assay.
4. DISCUSSION
We found that BV is associated with a signiﬁcant increase of
IL-8concentrationinthefemalegenitaltractofHIV-infected
and high-risk uninfected women, unrelated to IL-1β or IL-
6 activity. One cross-sectional study found no diﬀerence in
IL-8 levels in HIV-uninfected women with BV compared to
healthy controls, which is at variance with the current study
[12]. This may be explained because genital IL-8 concentra-
tions in healthy women are highly variable and, therefore,
may be diﬃcult to interpret in cross-sectional studies, unlike
the current design in which sequential specimens from the
samewomenwerecompared.Astudyevaluatinggenitaltract
cytokine expression in HIV-uninfected pregnant women be-
fore and after BV treatment, in which each woman served as
her own control, found signiﬁcant decreases in genital tract
IL-8 levels for women who cleared BV, as observed in the
current study [11]. Other studies have found no increase in
IL-6 associated with BV [16], as was observed in the current
study.
Lower IL-1β concentrations after BV clearance were ob-
served in the current study, which is consistent with studies
that have suggested women with BV have higher genital tract
IL-1β levels than healthy controls. Changes in IL1-β concen-
trations, in women with and without BV, were not statisti-
cally signiﬁcant. This may be attributable in part to the fact
that the current study evaluated HIV infected and high-risk
uninfected women whose baseline genital tract IL-1β may
have already been elevated compared to low-risk seronega-
tive women, and thus subtle changes may have been missed.
Although IL-1β is a potent inducer of IL-8, we observed
higher concentrations of IL-8 when women had BV com-
pared to levels after clearing BV, even after adjusting for IL-
1β in the multivariate analysis. Expression of IL-8 can also be
induced by IL-1β-independent mechanisms in cervical and
vaginal epithelial cells directly by microorganisms [17]. The
current study’s ﬁndings are consistent with observations of
Zhang et al. that infection with Mycoplasma hominis alters
cytokine gene expression in cervical epithelial cells, resulting
inupregulationofIL-8[18].Thelackofsigniﬁcantchangein
IL-1β or IL-6, despite signiﬁcant increase in IL-8 observed in4 Infectious Diseases in Obstetrics and Gynecology
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Figure 1: Plots of the estimated cumulative distribution function (CDF) curves for each cytokine by BV status, BV positive (BV+) or BV
negative (BV−), in pg/ml (log10), as well as the hazard ratios and corresponding 95% conﬁdence intervals estimated using a stratiﬁed Cox
proportional hazard model. IL-8 concentrations when women were BV+ (red line) were signiﬁcantly higher compared to IL-8 concentra-
tions (black line) after the women cleared BV (Hazard ratio = 3.8, 95% CI 1.419, 10.177). The diﬀerences in genital tract IL1-β and IL-6
concentrations when women were BV+ versus BV− were not statistically signiﬁcant.
this cohort, may be attributable to suppressive eﬀects of spe-
ciﬁc BV-associated organisms on the local mucosal immune
environment [5]. Further studies to identify whether some
of the more common organisms associated with BV, such as
GardnerellaorMobiluncusorothermorerecentlycharacter-
ized organisms are most responsible for the up regulation of
genital tract IL-8, are warranted [19].
The observed trends in genital tract cytokine concen-
trations were similar for HIV-infected and high-risk HIV-
negative women. The majority of HIV-infected women in
this study were on antiretroviral medications and had CD4 T
cell counts >200cells/μl and thus tended to be immunocom-
petent. Others have noted that immunocompromised HIV-
infectedpatientshavesigniﬁcantlyelevatedconcentrationsof
IL-8inplasmaandgenitaltractsecretions[20].Bydecreasing
vaginal IL-8 concentrations, the treatment for BV could po-
tentially decrease the HIV RNA levels in this compartment,
andthereby,decreasetheriskofHIVtransmission. Similarly,
in high-risk HIV-uninfected women, BV treatment may de-
crease susceptibility to HIV infection by reducing IL-8 con-
centrations [8].
Though there were relatively few women included in this
study, the comparison of vaginal cytokine concentrations
from the same individual with and without BV eliminated
individual variability. Moreover the use of archived samples,
known to be free of sexually transmitted infections that can
aﬀect cytokine levels in the vaginal tract, strengthened our
ability to evaluate the association between BV and vaginal
cytokine level. Future studies should include larger numbers
of HIV-infected women, thus enable a more thorough anal-
ysis of the possible eﬀect of antiretroviral therapy on vaginal
cytokine concentration.Phyllis Losikoﬀ et al. 5
Table 1: Median values and ranges of genital tract IL-8, IL-1β, and IL-6 concentrations (pg/ml) by bacterial vaginosis (BV) status, stratiﬁed
by HIV status.
Cytokine BV status (+/−) HIV+ median cytokine concentration (range) pg/ml HIV− median cytokine concentration (range) pg/ml
IL-8 BV+ 609.9 (33.3–12071.9) 508.0 (26.7–4987.6)
BV− 475.3 (40.7–7659.4) 46.4 (10–329.2)
IL-1β BV+ 58.1 (1–5665.4) 18.3 (1–396.8)
BV− 36.2 (< 0 1346.5) 1.9 (1–127.9)
IL-6 BV+ 0.7 (0.7–24.5) 0.7 (0.7–2.6)
BV− 7.44 (0.7–162.7) 0.7 (0.7–11.3)
Table 2: Median genital tract concentrations of IL-8, IL-1β, and IL-6 (pg/ml) at 3 consecutive clinic visits 6 months apart.
Cytokine Visit 1 BV− Visit 2 BV+ Visit 3 BV−
IL-1β 28.5 (13.9–50.8) 15.1 (1–396.8) 3.2 (1–127.7)
IL-8 86.9 (3.5–791.8) 680.7 (44.1–4967.6) 202.8 (9.9–405.6)
IL-61 0.7 (0.7–5.5) 0.7 (0.7–2.3) 0.7 (0.7–4.2)
1 >70% of IL-6 concentrations were below the level of detection of the assay.
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Figure 2: Genital tract IL-8 concentrations in pg/ml (log10)w e r e
evaluated at three consecutive visits for 2 high-risk HIV uninfected
(dotted lines) and 4 HIV infected women (solid lines) At baseline,
visit 1, none of these women had bacterial vaginosis. Women were
only included if data for all 3 visits was available.
In the light of the high prevalence of BV among HIV-
infected women and women at risk for HIV infection and
the association of BV with increased genital tract HIV RNA
levels, understanding the impact of BV on the immune envi-
ronment of the genital tract may facilitate eﬀective HIV pre-
vention. Interventions that are able to impede IL-8 produc-
tion and function may reduce genital tract HIV viral load
and impact transmission and acquisition of HIV. Interven-
tions that treat and prevent BV may also have an impact on
HIV transmission and prevention.
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